128 related articles for article (PubMed ID: 23264224)
1. Serum matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in esophageal cancer patients.
Groblewska M; Mroczko B; Kozlowski M; Niklinski J; Laudanski J; Szmitkowski M
Folia Histochem Cytobiol; 2012; 50(4):590-8. PubMed ID: 23264224
[TBL] [Abstract][Full Text] [Related]
2. The diagnostic value of the measurement of matrix metalloproteinase 9 (MMP-9), squamous cell cancer antigen (SCC) and carcinoembryonic antigen (CEA) in the sera of esophageal cancer patients.
Mroczko B; Kozłowski M; Groblewska M; Łukaszewicz M; Nikliński J; Jelski W; Laudański J; Chyczewski L; Szmitkowski M
Clin Chim Acta; 2008 Mar; 389(1-2):61-6. PubMed ID: 18155162
[TBL] [Abstract][Full Text] [Related]
3. Higher importance of interleukin 6 than classic tumor markers (carcinoembryonic antigen and squamous cell cancer antigen) in the diagnosis of esophageal cancer patients.
Łukaszewicz-Zając M; Mroczko B; Kozłowski M; Nikliński J; Laudański J; Szmitkowski M
Dis Esophagus; 2012 Apr; 25(3):242-9. PubMed ID: 21895853
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in the diagnosis of colorectal adenoma and cancer patients.
Groblewska M; Mroczko B; Gryko M; Kędra B; Szmitkowski M
Folia Histochem Cytobiol; 2010 Dec; 48(4):564-71. PubMed ID: 21478099
[TBL] [Abstract][Full Text] [Related]
5. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
6. Pre-treatment serum and plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) in gastric cancer patients.
Mroczko B; Groblewska M; Łukaszewicz-Zajac M; Bandurski R; Kedra B; Szmitkowski M
Clin Chem Lab Med; 2009; 47(9):1133-9. PubMed ID: 19728856
[TBL] [Abstract][Full Text] [Related]
7. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
[TBL] [Abstract][Full Text] [Related]
8. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of serum levels of matrix metalloproteinase 2 (MMP-2) and its tissue inhibitor (TIMP-2) in gastric cancer.
Mroczko B; Lukaszewicz-Zając M; Gryko M; Kędra B; Szmitkowski M
Folia Histochem Cytobiol; 2011; 49(1):125-31. PubMed ID: 21526499
[TBL] [Abstract][Full Text] [Related]
10. Elevated levels of serum metalloproteinase 9 in patients with esophageal squamous cell carcinoma.
Łukaszewicz-Zajac M; Mroczko B; Kozłowski M; Nikliński J; Laudański J; Szmitkowski M
Pol Arch Med Wewn; 2009 Sep; 119(9):558-63. PubMed ID: 19776700
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of serum macrophage-colony stimulating factor (M-CSF) in esophageal cancer patients and its comparison with classical tumor markers.
Łukaszewicz-Zajac M; Mroczko B; Kozłowski M; Nikliński J; Laudański J; Szmitkowski M
Clin Chem Lab Med; 2010 Oct; 48(10):1467-73. PubMed ID: 20604722
[TBL] [Abstract][Full Text] [Related]
12. Clinical and prognostic role of circulating MMP-2 and its inhibitor TIMP-2 in HCC patients prior to and after trans-hepatic arterial chemo-embolization.
Daniele A; Divella R; Quaranta M; Mattioli V; Casamassima P; Paradiso A; Garrisi VM; Gadaleta CD; Gadaleta-Caldarola G; Savino E; Maci R; Bellizzi A; Fazio V
Clin Biochem; 2014 Feb; 47(3):184-90. PubMed ID: 24355694
[TBL] [Abstract][Full Text] [Related]
13. Comparative evaluation of serum C-reactive protein (CRP) levels in the different histological subtypes of esophageal cancer (squamous cell carcinoma and adenocarcinoma of esophagus).
Lukaszewicz-Zając M; Mroczko B; Kozłowski M; Nikliński J; Laudański J; Siewko M; Szmitkowski M
J Clin Lab Anal; 2012 Feb; 26(2):73-81. PubMed ID: 22467322
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinase 2 (MMP-2) and their tissue inhibitor 2 (TIMP-2) in gastric cancer patients.
Łukaszewicz-Zając M; Mroczko B; Guzińska-Ustymowicz K; Pryczynicz A; Gryko M; Kemona A; Kędra B; Szmitkowski M
Adv Med Sci; 2013; 58(2):235-43. PubMed ID: 24384769
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer.
Schwandner O; Schlamp A; Broll R; Bruch HP
Int J Colorectal Dis; 2007 Feb; 22(2):127-36. PubMed ID: 16896992
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor.
Mroczko B; Lukaszewicz-Zajac M; Wereszczynska-Siemiatkowska U; Groblewska M; Gryko M; Kedra B; Jurkowska G; Szmitkowski M
Pancreas; 2009 Aug; 38(6):613-8. PubMed ID: 19629003
[TBL] [Abstract][Full Text] [Related]
17. [Diagnostic application of detecting AgNOR in peripheral blood T lymphocyte in patients with esophageal carcinoma].
Wang JY; Rong TH; Liang YR; Long H; Chen QL; Ma GW
Ai Zheng; 2004 May; 23(5):577-80. PubMed ID: 15142458
[TBL] [Abstract][Full Text] [Related]
18. Plasma level of tissue inhibitor of matrix metalloproteinase-1 but not that of matrix metalloproteinase-8 predicts survival in head and neck squamous cell cancer.
Pradhan-Palikhe P; Vesterinen T; Tarkkanen J; Leivo I; Sorsa T; Salo T; Mattila PS
Oral Oncol; 2010 Jul; 46(7):514-8. PubMed ID: 20371206
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of stromelysin-3 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer.
Sharma R; Chattopadhyay TK; Mathur M; Ralhan R
Oncology; 2004; 67(3-4):300-9. PubMed ID: 15557792
[TBL] [Abstract][Full Text] [Related]
20. Clinical Value of Serum p53 Antibody in the Diagnosis and Prognosis of Esophageal Squamous Cell Carcinoma.
Kunizaki M; Hamasaki K; Wakata K; Tobinaga S; Sumida Y; Hidaka S; Yasutake T; Miyazaki T; Matsumoto K; Yamasaki T; Sawai T; Hamamoto R; Nanashima A; Nagayasu T
Anticancer Res; 2018 Mar; 38(3):1807-1813. PubMed ID: 29491120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
